AZN Gets CHMP Nod for Label Expansion of Koselugo & Tezspire

Key Takeaways CHMP recommended AZN's Koselugo for adult NF1 patients with inoperable plexiform neurofibromas.Recommendation was backed by the phase III KOMET study showing improved response rates with Koselugo.CHMP recommended Tezspire for the treatment of adult patients with CRSwNP in the EU.AstraZeneca (AZN) announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) has recommended approval of its oral, selective MEK inhibitor, Koselugo (selumetinib ...